Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX
| Autor: | Kaufman, J. L., Dimopoulos, M., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Joy Ho, P., Kim, K., Takezako, N., Moreau, P., Sutherland, H. J., Magen, H., Iida, S., Kim, J. S., Miles Prince, H., Cochrane, T., Oriol, Albert, Bahlis, N. J., Chari, A., O'Rourke, L., Trivedi, S., Casneuf, T., Krevvata, M., Ukropec, J., Kobos, R., Avet-Loiseau, H., Usmani, S. Z., San-Miguel, J., Universitat Autònoma de Barcelona |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Population lcsh:RC254-282 Article Dexamethasone Disease-Free Survival Translocation Genetic Medical research Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Chromosomes Human Humans Progression-free survival education Lenalidomide Survival rate Multiple myeloma Cancer education.field_of_study medicine.diagnostic_test business.industry Antibodies Monoclonal Daratumumab Hematology medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Minimal residual disease Survival Rate Cytogenetic Analysis Chromosome Deletion Multiple Myeloma business medicine.drug Fluorescence in situ hybridization |
| Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Blood Cancer Journal, Vol 10, Iss 11, Pp 1-10 (2020) Blood Cancer Journal r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| ISSN: | 2044-5385 |
| Popis: | High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10–5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P P = 0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|